Interferon-gamma release assays piloted as a latent tuberculous infection screening tool in Canadian federal inmates
Ilan S. Schwartz(Fairview Health Services), Wendy Wobeser(Queen's University), B. Roscoe(Kingston Health Sciences Centre), Linda Panaro(Kingston Health Sciences Centre), Anna Majury(Public Health Ontario), T. Garrahan(Kingston Health Sciences Centre), C. Froats(Public Health Ontario), J. Smith(Kingston Health Sciences Centre), Ian Gemmill(University of Toronto), Edward Ellis(Public Health Agency of Canada), Wilma M. Hopman(Kingston General Hospital), Paxton Bach(University of British Columbia), F. Jamieson(Toronto Public Health), Rebecca Barkley(Kingston Health Sciences Centre)
Cited by 11
Related Papers
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
|New England Journal of Medicine|2020|1.4k
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19
|Annals of Internal Medicine|2020|548
Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology
|The Lancet Infectious Diseases|2021|281
Characterization of Environmental Sources of the Human and Animal Pathogen <i>Cryptococcus gattii</i> in British Columbia, Canada, and the Pacific Northwest of the United States
|Applied and Environmental Microbiology|2006|238
Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
|Open Forum Infectious Diseases|2020|215